Safety and Feasibility of Transcatheter Aortic Valve Replacement in Patients With Hematologic Neoplasms

Sep 23, 2026

Uploaded by Sarah

Transcatheter aortic valve replacement (TAVR) provides a less invasive alternative for patients with severe, symptomatic aortic stenosis (AS) who are poor surgical candidates. Patients with hematologic neoplasms are high-risk due to bleeding and infection, and have historically been excluded from TAVR studies. This series reports 10 patients with hematologic neoplasms undergoing successful TAVR, with minimal periprocedural complications, improved cardiovascular function, few long-term cardiac issues, and favorable 1-year survival.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages5

Reading Time13 min

AccessFree to download

Abstract

Background

Take-Home Message

Methods

Cases

Case 1

J A C C : C A S E R E P O R T S V O L . 3 1 , N O . 1 7 , 2 0 2 6 ª 2 0 2 6 T H E A U T H O R S . P U B L I S H E D BY E L S E V I E R O N B E H A L F O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O GY F O U N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E RT H E C C B Y-N C-N D L I C E N S E ( [h t t p : / / c r e a t i v e c o m m o n s . o r g / l i c e n s e s / b y-n c-n d / 4 . 0 /](h t t p : / / c r e a t i v e c o m m o n s . o r g / l i c e n s e s / b y-n c-n d / 4 . 0 /) ) . CARDIO-ONCOLOGY CLINICAL CASE SERIES Safety and Feasibility of Transcatheter Aortic Valve Replacement in Patients With Hematologic Neoplasms Nicholas W. Prinz, BA,a Joshua Thomas, MD,b Mevin A. Mathew, MD,c Jeet J. Mehta, MD,d Bibhu D. Mohanty, MDc ABSTRACT For patients with severe, symptomatic aortic stenosis (AS) who are poor surgical candidates, transcatheter aortic valve replacement (TAVR) offers a less invasive alternative to surgical valve replacement. Patients with hematologic neoplasms and severe AS are a high-risk subset, with increased risk of bleeding and infection, who have historically been excluded from clinical investigation in TAVR. Prior case reports have demonstrated successful TAVR in patients with hematologic neoplasms; however, there remains minimal literature on TAVR in this population. We present a series of 10 patients with hematologic neoplasms who underwent successful TAVR. Our cohort experienced minimal periprocedural complications and demonstrated marked improvement in cardiovascular function, with few long-term cardiac complications and favorable survival at 1 year post-procedure. These findings suggest that TAVR may be a feasible therapy inpatients with concomitant hematologic neoplasms and severe, symptomatic AS. (JACC Case Rep. 2026;31:107552)© 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)). BACKGROUND For patients with severe, symptomatic aortic stenosis (AS) who are poor surgical candidates, transcatheter aortic valve replacement (TAVR) provides a less invasive approach, aimed at improving symptoms, functional capacity, and survival. Patients with hematologic neoplasms represent a high-risk subset of patients, with an increased risk of bleeding and infection.1 As a result, these patients have classically been excluded from clinical investigation in TAVR. However, if not for AS, many of these patients can anticipate years of longevity with close hematologic follow-up and treatment.2 Existing literature regarding TAVR in patients with hematologic neoplasms is limited, with mixed case TAKE-HOME MESSAGE • Transcatheter aortic valve replacement appears to be a viable therapy for select patients with hematologic neoplasms and severe aortic stenosis, with minimal periprocedural complications and favorable survival at 1 year post-procedure. results. While some have demonstrated successful procedures with minimal complications, others have highlighted the increased perioperative morbidity and mortality associated with this high-risk population.3-7 Our case series adds to the existing literature and seeks to better characterize outcomes of TAVR inpatients with hematologic neoplasms and severe AS. From the aUSF Morsani College of Medicine, Tampa, Florida, USA; bDepartment of Internal Medicine, USF Morsani College of Medicine, Tampa, Florida, USA; cDepartment of Cardiovascular Sciences, USF Morsani College of Medicine, Tampa, Florida, USA; and the dDivision of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’institutions and Food and Drug Administration guidelines, including patient consent where a

FAQs

What outcomes did the case series report after TAVR in patients with hematologic neoplasms?

The series reported minimal periprocedural complications, marked improvement in cardiovascular function, few long-term cardiac complications, and favorable survival at 1 year post-procedure.

Sep 23, 2026

Uploaded by Sarah